Clearside Biomedical announced that its board of directors appointed George Lasezkay to be the company's interim chief executive officer, effective immediately. Lasezkay, a current member of the Clearside board of directors, succeeds Daniel White, who resigned as president and CEO and as a member of the Board of Directors to pursue other opportunities.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.35 USD | -2.88% | 0.00% | +15.38% |
05-13 | HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating | MT |
05-09 | Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.38% | 104M | |
+8.52% | 115B | |
+10.12% | 105B | |
-11.72% | 22.71B | |
+2.21% | 21.83B | |
-10.88% | 18.18B | |
-41.90% | 16.52B | |
-16.23% | 16.01B | |
+2.25% | 14.14B | |
+21.33% | 10.71B |
- Stock Market
- Equities
- CLSD Stock
- News Clearside Biomedical, Inc.
- Clearside Biomedical Announces Management Changes